GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 60.10 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-08-14
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-06-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-03-31 was 60.10K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2025-12-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2023-12-31 was -75.78K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2025 was 1.87K shares, a 86.00% decline from fiscal 2024.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 13.33K shares, a 410.26% increase from fiscal 2023.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 2.61K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2021 was 2.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 60.10K shares 10-Q · filed 2026-08-14 | 60.10K shares derived: sum of 3 quarters · filed 2026-08-14 | |
| 2026-03-31 | 60.10K shares 10-Q · filed 2026-05-15 | 60.10K shares derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | 1.87K shares 10-K · filed 2026-03-02 | ||
| 2025-09-30 | 1.87K shares 10-Q/A · filed 2026-03-06 | |||
| 2024-12-31 | 13.33K shares 10-K · filed 2026-03-02 | |||
| 2023-12-31 | -75.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -75.78K shares derived: sum of 2 quarters · filed 2025-02-21 | -75.78K shares derived: sum of 3 quarters · filed 2025-02-21 | 2.61K shares 10-K · filed 2025-02-21 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-01 | 78.39K shares 10-Q · filed 2023-11-01 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 78.39K shares 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | 78.39K shares 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 2.00K shares 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |